B&L buys Soothe eye drops from Alimera

Article

Bausch & Lomb (B&L) has acquired Soothe emolliant eye drops from Alimera Sciences.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A person in scrubs holds their hand outstretched toward the camera. A digital overlay gives the impression that the doctor or clinician is offering information about the future of eye care and retinal health. Image credit: ©sdecoret – stock.adobe.com

Advanced therapies in neovascular AMD and DMO: Experts weigh in

Hattie Hayes
March 12th 2025
Article

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A close-up of an eyeball looking at the tip of a syringe needle. There is a droplet of liquid coming from the syringe. Concept image for anti-VEGF and diabetic macular oedema. Image credit: ©kikkerdirk – stock.adobe.com

Renal dysfunction negatively impacts effect of diabetic macular oedema therapy

Lynda Charters
March 11th 2025
Article

Additionally, the prognosis of macular oedema may help clinicians evaluate renal function, investigators reported

Sun rays stretch over the horizon as a sun rises or sets against a blue sky. Image credit: ©Pavlo Vakhrushev – stock.adobe.com

Experts say revakinagene taroretcel-lwey approval may represent dawn of new treatments for neurodegenerative conditions

Sheryl Stevenson;Anat Loewenstein, MD, MHA;Rishi P. Singh, MD;Martin Friedlander, MD, PhD;Mohammad Rafieetary, OD, FAAO
March 10th 2025
Article

Clinicians react to the US approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) for macular telangiectasia type 2

A close-up of an elderly patient's face. They are administering eye drops. Image credit: ©photocrew – stock.adobe.com

Nicox SA shares research findings from NCX 470 Mont Blanc Phase 3 glaucoma trial

Jordana Joy
March 7th 2025
Article

The novel nitric oxide-donating bimatoprost eye drop is designed to lower IOP in patients with open-angle glaucoma or ocular hypertension

The Heidelberg Congress Center in Heidelberg, Germany. Image courtesy of Heidelberg Engineering.

Heidelberg Engineering announces two-day International SPECTRALIS Symposium

Hattie Hayes
March 7th 2025
Article

The event will include presentations on artificial intelligence, ocular imaging and surgical topics

© 2025 MJH Life Sciences

All rights reserved.